Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Branded Medicines Tranche Framework for London and South of England

NHS England

This public procurement record has 2 releases in its history.

Award

20 Aug 2024 at 14:23

Award Notice
Tender

05 Mar 2024 at 15:51

Tender Notice
Summary of the contracting process

NHS England has launched the "NHS Branded Medicines Tranche Framework for London and South of England," focusing on procuring pharmaceutical products. The procurement process is currently in the active tender stage, with an open procedure method. The framework comprises three lots, with key periods beginning on 1 September 2024, and options to extend up to 24 months at the authority's discretion. The total estimated value is £832,292,000, divided across multiple lots. The procurement falls under the goods category and targets delivery regions across England, including London, the South of England, the Midlands, and the North of England. The submission deadline for bids is 5 April 2024.

Businesses in the pharmaceutical industry have significant opportunities to expand by participating in this framework. The framework offers long-term supply potential to major NHS bodies, fostering stability and continuous growth. With an open procedure, a large number of suppliers can participate, making it suitable for both large enterprises like GlaxoSmithKline UK Limited and SMEs such as Manx Healthcare Ltd. Companies specialising in branded medicines and pharmaceuticals will find this framework particularly advantageous, allowing them to enhance their market presence while contributing to healthcare services.

How relevant is this notice?

Notice Information

Notice Title

NHS Branded Medicines Tranche Framework for London and South of England

Notice Description

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024<br/>Offer reference number: CM/PHR/22/5689<br/>CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.<br/>CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot Information

CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1

CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2

CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3

CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-0445bc
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/026491-2024
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£832,292,000 £100M-£1B
Lots Value
£832,293,000 £100M-£1B
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
20 Aug 20242 years ago
Submission Deadline
5 Apr 2024Expired
Future Notice Date
Not specified
Award Date
22 Jul 20242 years ago
Contract Period
1 Sep 2024 - 31 Aug 2025 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LEEDS
Postcode
LS1 4AP
Postcode Area
Leeds
Country
England
Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE42 Leeds
Delivery Location
Not specified
Local Authority
Leeds
Electoral Ward
Hunslet & Riverside
Westminster Constituency
Leeds South

Supplier Information

Number of Suppliers
31
Supplier Names

ACCORD-UK LTD

AstraZeneca

Aventis Pharma ltd t/a Sanofi

Aventis Pharma t/a Sanofi

BIOSIMILAR COLLABORATIONS IRELAND LIMITED

Biogen

Celltrion Healthcare United Kingdom Limited

Chugai Pharma UK Ltd

Dr.Reddy's Laboratories (UK) Limited

Eli Lilly and Company Ltd

Galapagos Biotech Ltd

Gedeon Richter UK Ltd

GlaxoSmithKline UK Limited

Janssen-Cilag Ltd

LEO Pharma

Manx Healthcare Ltd

Merck Sharpe and Dohme (UK) Limited

NOVARTIS PHARMACEUTICALS UK LIMITED

Napp Pharmaceuticals Ltd

Novartis Pharmaceuticals UK Ltd

Organon Pharmaceuticals UK Ltd

Orifarm UK

Pfizer Ltd

Roche Products Ltd

Sobi (Swedish Orphan Biovitrum Ltd)

Sun Pharma UK Ltd

Takeda UK Ltd

Teva UK Limited

Thornton and Ross Ltd

UCB Pharma Ltd (primary)

Zentiva Pharma UK Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...